Jeffrey Heier Sells 3,057 Shares of Ocular Therapeutix (NASDAQ:OCUL) Stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL) insider Jeffrey Heier sold 3,057 shares of the firm’s stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $8.28, for a total value of $25,311.96. Following the transaction, the insider directly owned 323,368 shares of the company’s stock, valued at approximately $2,677,487.04. This trade represents a 0.94% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Ocular Therapeutix Trading Up 0.9%

Ocular Therapeutix stock opened at $9.59 on Friday. Ocular Therapeutix, Inc. has a 12 month low of $5.78 and a 12 month high of $16.44. The company has a market capitalization of $2.09 billion, a price-to-earnings ratio of -6.66 and a beta of 0.90. The business’s fifty day simple moving average is $10.38 and its two-hundred day simple moving average is $11.59. The company has a current ratio of 15.39, a quick ratio of 15.32 and a debt-to-equity ratio of 0.11.

Ocular Therapeutix (NASDAQ:OCUL) last issued its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.04. The firm had revenue of $13.25 million during the quarter, compared to the consensus estimate of $16.13 million. Ocular Therapeutix had a negative return on equity of 70.68% and a negative net margin of 511.90%.The company’s revenue was down 22.4% on a year-over-year basis. During the same period last year, the company earned ($0.29) earnings per share. As a group, equities analysts predict that Ocular Therapeutix, Inc. will post -0.98 earnings per share for the current fiscal year.

Institutional Trading of Ocular Therapeutix

Large investors have recently modified their holdings of the company. Millennium Management LLC increased its position in Ocular Therapeutix by 3,136.1% during the third quarter. Millennium Management LLC now owns 3,855,706 shares of the biopharmaceutical company’s stock valued at $45,073,000 after acquiring an additional 3,736,560 shares during the last quarter. Alliancebernstein L.P. boosted its position in Ocular Therapeutix by 2,003.2% in the third quarter. Alliancebernstein L.P. now owns 3,424,439 shares of the biopharmaceutical company’s stock worth $40,032,000 after purchasing an additional 3,261,619 shares during the last quarter. Avoro Capital Advisors LLC grew its stake in shares of Ocular Therapeutix by 38.5% during the 3rd quarter. Avoro Capital Advisors LLC now owns 10,250,000 shares of the biopharmaceutical company’s stock valued at $119,822,000 after purchasing an additional 2,850,000 shares during the period. Vanguard Group Inc. increased its position in shares of Ocular Therapeutix by 26.3% during the 4th quarter. Vanguard Group Inc. now owns 11,575,193 shares of the biopharmaceutical company’s stock valued at $140,523,000 after purchasing an additional 2,411,953 shares during the last quarter. Finally, Janus Henderson Group PLC increased its position in shares of Ocular Therapeutix by 106.5% during the 4th quarter. Janus Henderson Group PLC now owns 4,229,202 shares of the biopharmaceutical company’s stock valued at $51,321,000 after purchasing an additional 2,180,702 shares during the last quarter. Institutional investors own 59.21% of the company’s stock.

Key Ocular Therapeutix News

Here are the key news stories impacting Ocular Therapeutix this week:

• Positive Sentiment: Director Richard Lindstrom bought 60,229 shares at ~ $7.66, increasing his stake ~32% — a notable insider purchase that signals confidence and provides direct demand support. SEC Filing – Lindstrom Form 4
• Positive Sentiment: Ocular will present detailed SOL‑1 data at the Macula Society meeting and host investor events — favorable readouts or constructive management commentary could be a major catalyst for the stock and offset recent weakness. SOL‑1 Presentation
• Positive Sentiment: Large institutional holders have been adding to positions (Vanguard, Avoro, TCG Crossover, Adage, Geode), which supports longer‑term demand even amid short‑term volatility. MarketBeat Institutional Summary
• Neutral Sentiment: Analyst coverage remains mixed-to-positive overall (consensus “Moderate Buy,” average target ~$23.78) — this keeps a bullish case intact but creates a wide range of expectations that earnings or SOL‑1 commentary could swing stock directionally. MarketBeat Summary
• Neutral Sentiment: Smaller, individual insider sales (e.g., Nadia Waheed sold 3,510 shares at ~$7.74) appear modest relative to major holdings and are unlikely alone to change long‑term conviction. SEC Filing – Waheed Form 4
• Negative Sentiment: Several executives/directors sold shares on Feb. 23 (Sanjay Nayak, Jeffrey Heier, Peter Kaiser and Pravin Dugel — Dugel sold 20,056 shares) at roughly $8.28; clustered insider selling increases available float and weighs on near‑term sentiment. SEC Filing – Dugel Form 4
• Negative Sentiment: Short interest jumped ~27.8% in February to ~14.7M shares (~6.9% of the float), elevating bearish pressure and the potential for sharper downside or volatile moves ahead of catalysts. (Days‑to‑cover ~3.0.)
• Negative Sentiment: Needham trimmed its price target to $18 (from $20), a downgrade that could temper enthusiasm among some growth/biotech investors despite other higher targets. Needham Price Target Cut

Wall Street Analysts Forecast Growth

OCUL has been the topic of a number of recent analyst reports. TD Cowen reiterated a “buy” rating on shares of Ocular Therapeutix in a report on Thursday, October 30th. Jefferies Financial Group reiterated a “buy” rating on shares of Ocular Therapeutix in a research note on Tuesday, February 17th. Needham & Company LLC reduced their target price on Ocular Therapeutix from $20.00 to $18.00 and set a “buy” rating for the company in a report on Friday, February 20th. Chardan Capital restated a “buy” rating and issued a $21.00 price target on shares of Ocular Therapeutix in a research note on Wednesday, February 18th. Finally, Wall Street Zen raised Ocular Therapeutix from a “sell” rating to a “hold” rating in a report on Saturday, February 7th. Twelve investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $23.78.

About Ocular Therapeutix

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.